Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease

作者：Greiman Alyssa K^*; Keane Thomas E

来源：Current Urology Reports, 2017, 18(6): 41.

DOI：10.1007/s11934-017-0688-5

• Androgen deprivation
• Cardiovascular disease
• Gonadotropin-releasing hormone agonist
• Gonadotropin-releasing hormone antagonist
• Degarelix

Purpose of Review Androgen deprivation therapy (ADT) is a mainstay of treatment for advanced prostate cancer. Several studies have reported an association between ADT and an increase in cardiovascular events, especially in those receiving gonadotropin-releasing hormone (GnRH) agonists compared to GnRH antagonists. We review the body of literature reporting the association of ADT and cardiovascular morbidity, and discuss the proposed mechanism of cardiovascular disease due to ADT including metabolic changes that may promote atherosclerosis and local hormonal effects that may increase plaque rupture and thrombosis.
Recent Findings GnRH agonists appear to increase the risk of cardiovascular morbidity by 20-25% in men on these agents compared those who do not receive ADT. GnRH antagonists may appear to have halve this risk while improving PSA progression-free survival.
Summary GnRH antagonists may be superior to GnRH agonists for patients with significant cardiovascular disease, significant metastatic disease burden, or severe lower urinary tract symptoms.

• 出版日期2017-6